Norton Rose Advises on the Recapitalisation of Italian Food and Cosmetics Group

International legal practice Norton Rose Studio Legale has advised the Italian entrepreneur, Canio Mazzaro, on the preliminary phase of the recapitalisation of Bioera, a listed Italian food and cosmetics group currently in administration. The court of Reggio Emilia has approved Mazzaro’s offer to acquire and recapitalise Bioera, including his plan to carry out two Euro 9 million capital increases. The objective of the recapitalisation is to reinforce Bioera’s finances, restore its position as a leading company in the bio-food market and relaunch trading of Bioera shares by June 2011.

More >>

Tags:  Norton Rose Fulbright

Norton Rose Advises Sumitomo on Acquisition of 10 PV Solar Parks

International legal practice Norton Rose Studio Legale has advised Sumitomo Corporation on the acquisition of 85 percent stakes in two Italian solar power subsidiaries of German-based S.A.G. Solarstrom. As a result of an agreement signed on 3 February 2011, the Japanese-based trading conglomerate will own 10 PV solar parks located in southern Italy having total capacity generation of 9,700kw.

More >>

Tags:  Norton Rose Fulbright

Shearman & Sterling Advises on Secondary Offering and Repurchase of Quest Diagnostics’ Common Stock

Shearman & Sterling represented Quest Diagnostics Incorporated in connection with an underwritten public offering of 15,377,600 shares of Quest’s common stock held by GlaxoSmithKline plc., its largest stockholder. Concurrently with the public offering, Quest repurchased the 15,377,551 shares of its common stock from GlaxoSmithKline plc. Following this offering and the repurchase, GlaxoSmithKline plc no longer holds common stock of Quest. Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC acted as joint bookrunners for the offering. Quest Diagnostics is the world’s leading provider of diagnostic testing, information and services.

More >>

Tags:  Shearman & Sterling LLP

Davis Polk – Savient Pharmaceuticals, Inc. $230 Million Convertible Senior Notes Offering

Davis Polk advised J.P. Morgan Securities LLC as the sole book-running manager and representative of the underwriters on a registered public offering by Savient Pharmaceuticals, Inc. of $230 million aggregate principal amount of its 4.75% convertible senior notes due 2018 (which included the full exercise of the over-allotment option). 

More >>

Tags:  Davis Polk & Wardwell LLP

Cooley Advises Epocrates, Inc. on its Initial Public Offering

Cooley LLP announced that it represented Epocrates, Inc. (NASDAQ: EPOC), in connection with its initial public offering of common stock.  Underwriters include J.P. Morgan Securities LLC and Piper Jaffray & Co., serving as joint book-running managers, and William Blair & Company, L.L.C. and JMP Securities LLC, acting as co-managers.

More >>

Tags:  Cooley LLP